ArticleJournal of healthcare engineering2022
Cancer Categorization Using Genetic Algorithm to Identify Biomarker Genes.
Article in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Heuristic computing with active set method for the nonlinear Rabinovich-Fabrikant model.Heliyon · 2023Article
- A Breast Cancer Image Classification Algorithm with 2c Multiclass Support Vector Machine.Journal of healthcare engineering · 2023Article
- Retracted: Cancer Categorization Using Genetic Algorithm to Identify Biomarker Genes.Journal of healthcare engineering · 2023Article
Corrections and comments
- Retraction · 2023-10-11Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the microarray gene expression data, there are a large number of genes that are expressed at varying levels of expression. Given that there are only a few critically significant genes, it is challenging to analyze and categorize datasets that span the whole gene space. In order to aid in the diagnosis of cancer disease and, as a consequence, the suggestion of individualized treatment, the discovery of biomarker genes is essential. Starting with a large pool of candidates, the parallelized minimal redundancy and maximum relevance ensemble (mRMRe) is used to choose the top m informative genes from a huge pool of candidates. A Genetic Algorithm (GA) is used to heuristically compute the ideal set of genes by applying the Mahalanobis Distance (MD) as a distance metric. Once the genes have been identified, they are input into the GA. It is used as a classifier to four microarray datasets using the approved approach (mRMRe-GA), with the Support Vector Machine (SVM) serving as the classification basis. Leave-One-Out-Cross-Validation (LOOCV) is a cross-validation technique for assessing the performance of a classifier. It is now being investigated if the proposed mRMRe-GA strategy can be compared to other approaches. It has been shown that the proposed mRMRe-GA approach enhances classification accuracy while employing less genetic material than previous methods. Microarray, Gene Expression Data, GA, Feature Selection, SVM, and Cancer Classification are some of the terms used in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.